MedPAC’s Message To Congress: Drug Pricing Still Needs Attention

The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.

MEDPAC's reform efforts will continue to inject uncertainty into Part B • Source: Shutterstock

When Medicare Payment Advisory Commission Principal Policy Analyst Nancy Ray began her 2 September presentation on ideas to overhaul the federal payment system for physician-administered drugs in Medicare Part B, she noted a major development since the commissioners last assembled.

“Since the June report, the Inflation Reduction Act contains changes to Part B drug payment,” Ray said. “However,” she added,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access